Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Preventive care services and health behaviors in children with fragile X syndrome.

Gilbertson KE, Jackson HL, Dziuban EJ, Sherman SL, Berry-Kravis EM, Erickson CA, Valdez R.

Disabil Health J. 2019 May 3. pii: S1936-6574(19)30064-0. doi: 10.1016/j.dhjo.2019.04.005. [Epub ahead of print]

PMID:
31118158
2.

A Pilot Quantitative Evaluation of Early Life Language Development in Fragile X Syndrome.

Reisinger DL, Shaffer RC, Pedapati EV, Dominick KC, Erickson CA.

Brain Sci. 2019 Jan 29;9(2). pii: E27. doi: 10.3390/brainsci9020027.

3.

Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis: a pilot study.

Hong MP, Eckert EM, Pedapati EV, Shaffer RC, Dominick KC, Wink LK, Sweeney JA, Erickson CA.

J Neurodev Disord. 2019 Jan 21;11(1):1. doi: 10.1186/s11689-019-9262-4.

4.

Best Practices in Fragile X Syndrome Treatment Development.

Erickson CA, Kaufmann WE, Budimirovic DB, Lachiewicz A, Haas-Givler B, Miller RM, Weber JD, Abbeduto L, Hessl D, Hagerman RJ, Berry-Kravis E.

Brain Sci. 2018 Dec 15;8(12). pii: E224. doi: 10.3390/brainsci8120224.

5.

Author Correction: Impaired perceptual learning in a mouse model of Fragile X syndrome is mediated by parvalbumin neuron dysfunction and is reversible.

Goel A, Cantu DA, Guilfoyle J, Chaudhari GR, Newadkar A, Todisco B, de Alba D, Kourdougli N, Schmitt LM, Pedapati E, Erickson CA, Portera-Cailliau C.

Nat Neurosci. 2019 Jan;22(1):143. doi: 10.1038/s41593-018-0273-3.

PMID:
30442922
6.

Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders.

Lamy M, Erickson CA.

Curr Probl Pediatr Adolesc Health Care. 2018 Oct;48(10):250-264. doi: 10.1016/j.cppeds.2018.08.015. Epub 2018 Sep 24.

PMID:
30262163
7.

Impaired perceptual learning in a mouse model of Fragile X syndrome is mediated by parvalbumin neuron dysfunction and is reversible.

Goel A, Cantu DA, Guilfoyle J, Chaudhari GR, Newadkar A, Todisco B, de Alba D, Kourdougli N, Schmitt LM, Pedapati E, Erickson CA, Portera-Cailliau C.

Nat Neurosci. 2018 Oct;21(10):1404-1411. doi: 10.1038/s41593-018-0231-0. Epub 2018 Sep 24. Erratum in: Nat Neurosci. 2019 Jan;22(1):143.

8.

Emotion Regulation Intensive Outpatient Programming: Development, Feasibility, and Acceptability.

Shaffer RC, Wink LK, Ruberg J, Pittenger A, Adams R, Sorter M, Manning P, Erickson CA.

J Autism Dev Disord. 2019 Feb;49(2):495-508. doi: 10.1007/s10803-018-3727-2.

PMID:
30143951
9.

A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder.

Wink LK, Adams R, Horn PS, Tessier CR, Bantel AP, Hong M, Shaffer RC, Pedapati EV, Erickson CA.

J Autism Dev Disord. 2018 Sep;48(9):3051-3060. doi: 10.1007/s10803-018-3562-5.

PMID:
29644582
10.

SPARK: A US Cohort of 50,000 Families to Accelerate Autism Research.

SPARK Consortium. Electronic address: pfeliciano@simonsfoundation.org; SPARK Consortium.

Neuron. 2018 Feb 7;97(3):488-493. doi: 10.1016/j.neuron.2018.01.015.

11.

Risperidone Treatment for Irritability in Fragile X Syndrome.

Dominick KC, Wink LK, Pedapati EV, Shaffer R, Sweeney JA, Erickson CA.

J Child Adolesc Psychopharmacol. 2018 May;28(4):274-278. doi: 10.1089/cap.2017.0057. Epub 2018 Feb 2.

PMID:
29394101
12.

A randomized controlled trial of levodopa in patients with Angelman syndrome.

Tan WH, Bird LM, Sadhwani A, Barbieri-Welge RL, Skinner SA, Horowitz LT, Bacino CA, Noll LM, Fu C, Hundley RJ, Wink LK, Erickson CA, Barnes GN, Slavotinek A, Jeremy R, Rotenberg A, Kothare SV, Olson HE, Poduri A, Nespeca MP, Chu HC, Willen JM, Haas KF, Weeber EJ, Rufo PA.

Am J Med Genet A. 2018 May;176(5):1099-1107. doi: 10.1002/ajmg.a.38457. Epub 2017 Sep 25.

13.

Diagnosing Autism Spectrum Disorder from Brain Resting-State Functional Connectivity Patterns Using a Deep Neural Network with a Novel Feature Selection Method.

Guo X, Dominick KC, Minai AA, Li H, Erickson CA, Lu LJ.

Front Neurosci. 2017 Aug 21;11:460. doi: 10.3389/fnins.2017.00460. eCollection 2017.

14.

Erratum to: Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome.

Ethridge LE, White SP, Mosconi MW, Wang J, Pedapati EV, Erickson CA, Byerly MJ, Sweeney JA.

Mol Autism. 2017 Jul 26;8:38. doi: 10.1186/s13229-017-0150-z. eCollection 2017.

15.

Eye gaze and pupillary response in Angelman syndrome.

Hong MP, Guilfoyle JL, Mooney LN, Wink LK, Pedapati EV, Shaffer RC, Sweeney JA, Erickson CA.

Res Dev Disabil. 2017 Sep;68:88-94. doi: 10.1016/j.ridd.2017.06.011. Epub 2017 Jul 24.

PMID:
28750207
16.

Lurasidone for the treatment of irritability and anger in autism spectrum disorders.

McClellan L, Dominick KC, Pedapati EV, Wink LK, Erickson CA.

Expert Opin Investig Drugs. 2017 Aug;26(8):985-989. doi: 10.1080/13543784.2017.1353600. Epub 2017 Jul 24. Review.

PMID:
28685626
17.

Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.

Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, King MK, Abbeduto L, Kaufmann WE.

J Neurodev Disord. 2017 Jun 12;9:14. doi: 10.1186/s11689-017-9193-x. eCollection 2017. Review.

18.

Fragile X targeted pharmacotherapy: lessons learned and future directions.

Erickson CA, Davenport MH, Schaefer TL, Wink LK, Pedapati EV, Sweeney JA, Fitzpatrick SE, Brown WT, Budimirovic D, Hagerman RJ, Hessl D, Kaufmann WE, Berry-Kravis E.

J Neurodev Disord. 2017 Jun 12;9:7. doi: 10.1186/s11689-017-9186-9. eCollection 2017. Review.

19.

Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety.

Schaefer TL, Davenport MH, Grainger LM, Robinson CK, Earnheart AT, Stegman MS, Lang AL, Ashworth AA, Molinaro G, Huber KM, Erickson CA.

J Neurodev Disord. 2017 Jun 12;9:6. doi: 10.1186/s11689-017-9184-y. eCollection 2017.

20.

Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome.

Ethridge LE, White SP, Mosconi MW, Wang J, Pedapati EV, Erickson CA, Byerly MJ, Sweeney JA.

Mol Autism. 2017 Jun 7;8:22. doi: 10.1186/s13229-017-0140-1. eCollection 2017. Erratum in: Mol Autism. 2017 Jul 26;8:38.

Supplemental Content

Loading ...
Support Center